Aptevo Therapeutics Inc.
APVO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,089 | $3,878 | $20,681 | $64,307 |
| - Cash | $8,714 | $16,904 | $22,635 | $45,044 |
| + Debt | $4,629 | $5,397 | $9,535 | $16,715 |
| Enterprise Value | -$1,996 | -$7,629 | $7,581 | $35,978 |
| Revenue | $0 | $0 | $3,114 | $12,292 |
| % Growth | – | -100% | -74.7% | – |
| Gross Profit | -$352 | $0 | $3,114 | $12,292 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$23,778 | -$28,311 | -$27,740 | -$20,256 |
| % Margin | – | – | -890.8% | -164.8% |
| Net Income | -$24,130 | -$17,411 | $8,027 | -$28,457 |
| % Margin | – | – | 257.8% | -231.5% |
| EPS Diluted | -1,747.68 | -46,335 | 51,217 | -197,647 |
| % Growth | 96.2% | -190.5% | 125.9% | – |
| Operating Cash Flow | -$23,785 | -$11,730 | -$21,022 | -$21,679 |
| Capital Expenditures | $0 | $0 | -$29 | -$713 |
| Free Cash Flow | -$23,785 | -$11,730 | -$21,051 | -$22,392 |